Enroll Get Info Pack
1-877-235-1997

References

  1. Aldenhoven M and Kurtzberg J. Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future directions. Cytotheraphy 2015;17:765-74.
  2. Armson BA, Allan DS, Casper RF. Umbilical Cord Blood: Counselling, Collection, and Banking. SOGC Clinical Practice Guide. JOGC. Sept. 2015; 328: 832-844.
  3. Applebaum FR. Pursuing the goal of a donor for everyone in need. N Engl J Med. 2012;367(16):1555-1556.Ball LM1, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, Avanzini MA, Conforti A, Bertaina A, Giorgiani G, Jol-van der Zijde CM, Zecca M, Le Blanc K, Frassoni F, Egeler RM, Fibbe WE, Lankester AC, Locatelli F. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Heamatol. 2013 Nov; 163(4):501-9.
  4. Ball LM1, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, Avanzini MA, Conforti A, Bertaina A, Giorgiani G, Jol-van der Zijde CM, Zecca M, Le Blanc K, Frassoni F, Egeler RM, Fibbe WE, Lankester AC, Locatelli F. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Heamatol. 2013 Nov; 163(4):501-9.
  5. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013 May 14; 122: 491-498.
  6. Ballen KK, Spitzer TR, Yeap B, Steve M, Dey BR, Attar E et al. Excellent disease-free survival after double cord blood transplantion using a reduced intensity chemotherapy only conditioning regimen in a diverse adult population. ASH Annual Meeting Abastracts 2005; 106: 2048.
  7. Barker J et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a match-pair ana;ysis. Blood 2001;97:2957-61.
  8. Barker JN, Weisdorf DJ, DeFor TE et al. Transplantion of 2 partially HLA matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343-1347.
  9. Bhatia M, Walters M. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant, 2008; 41:109-17.
  10. Blum B1, Benvenisty N. The tumorigenicity of human embryonic stem cells.Adv Cancer Res.2008;100:133-58.
  11. Boelens JJ, Aldenhoven M, Purtill D,et al. Eurocord; Inborn Errors Working Party of European Blood and Marrow Transplant group; Duke University Blood and Marrow Transplantation Program; Centre for International Blood and Marrow Research. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013;121:3981-7.
  12. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. 2004;10:2385–2389.
  13. Broxmeyer H et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. PNAS 1989;86;3828-32.
  14. Broxmeyer H, Lee M-R, Hangoc G, Cooper S, Prasain N, Kim Y-J, Mallett C, YE Z, Witting S, Cornetta K, Cheng K, Linzhao C, Yoder M. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells and isolation of endothelial progenitors from 21-23.5 year cryopreserved cord blood. Blood, 2011;117:4773-7.
  15. Broxmeyer HE, Srour EF, Hangoc G, Cooper S, Anderson SA, Bodine DM. High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc National Acad Sci USA 2003; 100: 645– 50.
  16. Carroll J. Human cord blood for the hypoxic-ischemic neonate. Pediatr Res. 2012;71:459-63.
  17. Ciccoioppo R, Gallia A, Sqaraella A, Kruzliak P, Gobbi PG, Corazza GR. Long-Term Follow-up of Crohn Disease Fistulas After Local Injections of Bone Marrow-Derived Mesenchymal Stem Cells. Mayo Clin Proc. 2015 Jun;90(6):747-55.
  18. Chhabra P, Brayman KL. Stem cell therapy to cure type 1 diabetes: from hype to hope. Stem Cells Transl Med. 2013;2:328-36. Review.
  19. Christodoulou, Kilisis FN, Papaevangeliou D, Zoumpourlis V. Comparative Evaluationof Human Mesenchymal Stem Cells for Fetal (Wharton’s Jelly) and Adult (Adipost Tissue) Orgin during Prolonged In Vitro Expansion; Considerations for Cytotherapy. Stem cells International. 2013;246134.
  20. Clinicaltrials.gov, based on data as of October 2015. Survey conducted by Cells for Life Inc.
  21. Cotton M et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic Encephalopathy. J Pediatr 2014;164:973-9.
  22. Cutler C, Ballen KK.Improving outcomes in umbilical cord blood transplantation: state of the art. Blood Rev. 2012;26:241-6. Review.
  23. Da Costa V, O’Grady G, Jackson L, Kaylie D, Raynor E. Improvements in sensorineural hearing loss after cord blood transplant in patients with mucopolysaccharidosis. Arch Otolaryngol Head Neck Surg. 2012;138:1071-6.
  24. Damien P, Allan D. Regenerative therapy and immune modulation using umbilical cord blood-derived cells.Biol Blood Marrow Transplant. 2015 Jun 12. pii: S1083-8791(15)00379-1. doi: 10.1016/j.bbmt.2015.05.022.
  25. Eapen M, Rubinstein P, Zhang JM et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study. Lancet 2007; 369: 1947–1954.
  26. Ende M, Ende N. Hematopoietic transplantation by means of fetal (cord) blood. Virginia Med Mon. 1972;99:276–80.
  27. Escolar ML, Poe MD, Provenzale JM et al. Transplantation of umbilical cord blood in babies with infantile Krabbe’s disease. NEJM 2005; 352: 2069-2081.
  28. Fiorina P, Voltarelli J, Zavazava N.Immunological applications of stem cells in type 1 diabetes.Endocr Rev. 2011;32:725-54.
  29. Frey M et al. Umbilical cord blood cell transplantation. Semin Oncol Nurs 2009 May; 25(2): 115-9.
  30. Fruchtman SM, Hurlet A, Dracker R et al. The successful treatment of severe aplastic anemia with autologous cord blood transplantation. Biol Blood Marrow Transplant, 2004; 10: 741-2.
  31. Garbuzova-Davis S. et al. Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS ONE. 2008 June 25; 3(6).
  32. Gluckman E et al. Outcome of cord blood transplantation from related and unrelated donors. NEJM 1997;337:373-81.
  33. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from HLA-identical sibling. N Engl J Med 1989; 79(7): 1874:1881.
  34. Gluckman E, Rocha V, Arcese W, Michael G, Sanz G, Chan KW et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32: 397-407.
  35. Gluckman E, Rocha V, Boyer-Chammard A, et al. Eurocord transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 1997;337(6):373-381.
  36. Gluckman E, Koegler G, Rocha V. Human leukocyte antigen matching in cord blood transplantion. Semin Hematol 2005; 42: 85-90.
  37. Gluckman E. History of cord blood transplantation. Bone Marrow Transplantation 2009; 44:621-626.
  38. Goodwin HS, Bicknese AR, Chien SN, Bogucki BD, Quinn CO, Wall DA. Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers.Biol Blood Marrow Transplant. 2001;7:581-8.
  39. Goulmy E et al. Mismatches of minor histocompatibility antigens between HLA_identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. NEJM 1996;334:281-5.
  40. Haller, M.J. et al. Autologous umbilical cord blood infusion for type 1 diabetes. Exp. Hematology. 2008; 36: 710-715.
  41. Harris D, Rogers I. Umbilical cord blood: a unique source of pluripotent stem cells for regenerative medicine. Curr Stem Cell Res Ther 2007; 2:301-309.
  42. Hayani A, et al. First report of autologous cord blood transplantation in treatment of a child with leukemia. Pediatrics. 2007; 119:296-300.
  43. Hong SH, Gang EJ, Jeong JA, et al. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. Biochem Biophys Res Commun.2005 May 20;330:1153-61.
  44. https://clinicaltrials.gov/, accessed June 2015.
  45. Hsieh JY, Fu YS, Chang SJ, Tsuang YH, Wang HW. Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton’s jelly of umbilical cord. Stem Cells Dev. Dec 2010;19(12):1895-910.
  46. Huo W1, Liu X1, Tan C1, Han Y1, Kang C1, Quan W1, Chen J1. Stem cell transplantation for treating stroke: status, trends and development.Neural Regen Res.2014 Sep 1;9(17):1643-8.
  47. Jubert C, Wagner E, Bizier S, Vachon MF, Duval M, Champagne M. Length of cord blood unit cryopreservation does not impact hematopoietic engraftment. Transfusion 2008; 48:2028-29.
  48. Kim YS, Kwon OR, Choi YJ, Suh DS, Heo DB, Koh YG. Comparative Matched-Pair Analysis of the Injection Versus Implantation of Mesenchymal Stem Cells for Knee Osteoarthritis. Am J Sports Med. 2015 Nov; 43(11):2738-46.
  49. Kurtzberg J et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. NEJM 1996;335:157-66.
  50. Kurtzberg et al. Update on umbilical cord blood transplantation. Current Opinion Pediatrics, 2009 Feb: 21(1): 22-9.
  51. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study: clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematological malignancies. Blood 2008; 112: 4318-4327.
  52. Kwon M, Balsalobre P, Serrano SD, et al.Single cord blood combined with HLA-mismatched third party donor cells: comparable results to matched unrelated donor transplantation in high-risk patients with hematologic disorders.Biol Blood Marrow Transplant. 2013 ;19:143-9.
  53. Laporte JP et al. Cord blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. NEJM 1996;335:373-81.
  54. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N. Engl. J Med 2001; 344: 1815–1822.
  55. Lee et al. Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy.J Transl Med. 2012 Mar 23;10:58.
  56. Liao Y, Geyer MB, Yang AJ, Cairo MS.Cord blood transplantation and stem cell regenerative potential.Exp Hematol. 2011;39:393-412.
  57. Liao W, Huang N, Yu J, Jares A, Yang J, Zieve G, Avila C, Jiang X, Zhang XB, Ma Y.Direct Conversion of Cord Blood CD34+ Cells Into Neural Stem Cells by OCT4. Stem Cells Transl Med. 2015 May 13. pii: sctm.2014-0289. [Epub ahead of print]
  58. Liu H, Rich ES, Godley L et al.Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.Blood. 2011;118:6438-45.
  59. Locatelli F et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease.Blood 2003;101:2137-43.
  60. Locatelli F, Kabbara N, Ruggeri A, et al.Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling.Blood. 2013 May 21.
  61. Majhail N, Weisdorf D, Wagner J et al. Comparable results of umbilical cord blood and HLA-matched sibling donor preparative regimen for advanced Hodgkin lymphoma. Blood, 2006; 107: 3804-7.
  62. Min et al. Umbilical Cord Blood Therapy Potentiated with Erythropoietin for Children with Cerebral Palsy: A Double-blind, Randomized, Placebo-Controlled Trial Stem Cells 2013;31:581.
  63. Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J Stem Cells. April 2014;6(2):195-202.
  64. Neitfeld J, Pasquini M, Logan B, Verter F, Horowitz M. Lifetime probabilities of hematopoietic stem cell transplantation in the US. 2008; 13:316-22.
  65. Newman M Davis C, Borlongan C et al. Transplantion of human umbilical cord blood cells in the repair of CNS diseases. Expert Opin. Biol Ther 2004; 4:121-30.
  66. Okamura K et al. Successful Cord Blood Transplantation using a reduced-intensity conditioning regimen for advanced childhood-onset cerebral adrenoleukodystrophy. Pediatric Transplant, 2009 May; 13:130-133.
  67. Parent’s Guide to Cord Blood Foundation. www.parentsguidetocordblood.org. 2007 – 2015.
  68. Pasquini MC et al. The likelihood of hematopoietic stem cell transplantation (HCT) in the United States: implications for umbilical cord blood storage. Blood 2005; 11.
  69. Pozzobon et al. Fetal stem cells and skeletal muscle regeneration: a therapeutic approach. Ffront Aging Neurosci. 2014;222.
  70. Reed W, Smith R, Dekovic F et al. Comprehensive banking of sibling donor cord blood for children with malignant and nonmalignant disease. Blood 2003;101:351-7.
  71. Rocha V, Chastang C, Souillet G et al. Related cord blood transplants: the Eurocord experience from 78 transplants. Eurocord Transplant group, Bone Marrow Transplant, 1998; 21 (supple. 3): 559-62.
  72. Rocha V1, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.N Engl J Med.2000 Jun 22;342(25):1846-54.
  73. Rocha V, Labopin M, Sanz G et al. Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. NEJM 2004;351:2276-85.
  74. Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients, Bone Marrow Transplant, 2008; 41:207-14.
  75. Rocha V, Labopin M, Ruggeri A et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies.Transplantation. 2013;95:1284-91.
  76. Rosenkranz K, Meier C Umbilical cord blood cell transplantation after brain ischemia–from recovery of function to cellular mechanisms.Ann Anat. 2011;193:371-9.
  77. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, Berkowitz RL, Cabbad M, Dobrila NL, Taylor PE, Rosenfield RE, Stevens CE .Outcomes among 562 recipients of placental-blood transplants from unrelated donors.N Engl J Med. 1998 Nov 26;339(22):1565-77.
  78. Sandberg P et al. Umbilical cord blood derived stem cells and brain repair, Ann NY Acad Sci 2005: 1049:67-83.
  79. Scaradavou A, Brunstein CG, Eapen M et al.Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.Blood. 2013;121:752-8.
  80. Schu et al. Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine. Sept 2012;16(9):2094-2103.
  81. Sharma et al. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 2014, 54:1418-37.
  82. Shenoy S. Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants. Stem Cells Transl Med. 2013;2:337-40.
  83. Sodian R1, Schaefermeier P, Abegg-Zips S, Kuebler WM, Shakibaei M, Daebritz S, Ziegelmueller J, Schmitz C, Reichart B. Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann Thorac Surg. 2010 Mar;89(3):819-28.
  84. Staba SL, Escolar ML, Poe M, et al. Cord blood transplants from unrelated donors in patients with Hurler’s syndrome. NEJM 2004; 305: 1960-1969.
  85. Szabolcs P and Cairo MS. Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol. 2010 Jan;47(1):22-36
  86. Tissue Regeneration Therapeutics Inc. Website: https://www.verypowerfulbiology.com
  87. Tse W and Laughlin M. Umbilical Cord Blood Transplantation: A New Alternative Option. Hematology Am Soc Hematol Educ Program. 2005;377-83.
  88. Tucunduva L1, Volt F, Cunha R, Locatelli F, Zecca M, Yesilipek A, Caniglia M, Güngör T, Aksoylar S, Fagioli F, Bertrand Y, Addari MC, de la Fuente J, Winiarski J, Biondi A, Sengeloev H, Badell I, Mellgren K, de Heredia CD, Sedlacek P, Vora A,Rocha V,Ruggeri A,Gluckman E;Eurocord and the EBMT Paediatric working partyCombined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases.Br J Haematol.2015 Apr;169(1):103-10. doi: 10.1111/bjh.13267. Epub 2014 Dec 18.
  89. Van Besien K, Liu H, Jain N, Stock W, Artz A.Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.Biol Blood Marrow Transplant. 2013;19:682-91.
  90. Van Rood J, Stevens C, Smits J, Carrier C, Carpenter C, Scaradavou A. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in haematological malignancies. Proc Natl Acad Sci 2009;106:19952-7.
  91. Wagner J, Kernan N, Steinbuch M, et al. Allogeneic sibling umbilical cord blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346: 214 -219.
  92. Willing A, Eve D, Sanberg P. Umbilical cord blood transfusions for prevention of progressive brain injury and induction of neural recovery: an immunological perspective. Regen Med, 2007; 2:457-64.
  93. World Marrow Donor Association (WMDA) Annual Report, 2006 – 2014.
  94. Zhao Y1, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, Zhang Y, Diao Y, Li Y, Chen Y, Sun X, Fisk MB, Skidgel R, Holterman M, Prabhakar B, Mazzone T Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med.2012 Jan 10;10:3. doi: 10.1186/1741-7015-10-3.

Get Info Pack

Take the first step to learn about cord blood and cord tissue banking today!

Cells For Life

Our Advantage
Cord Blood
Cord Tissue
Pricing
FAQ

Learn More

Free Prenatal Classes
Healthcare Professionals
Returning Customers
Gift Registry
Privacy Policy

Contact Us

Mon – Fri: 9am – 5pm
Fax: 905.472.2185
Toll Free: 1.877.235.1997
info.cfl@cellsforlife.com

add chat to your website
close-link
Copy link
CopyCopied
Powered by Social Snap